Tesaglitazar a dual peroxisome proliferator-activated receptor alpha/gamma agonist reduces atherosclerosis in female low density lipoprotein receptor deficient mice

摘要

ObjectiveThe transcription factors, peroxisome proliferator-activated receptors (PPAR) alpha (α) and gamma (γ), which are involved in lipid and glucose homeostasis, also exert modulatory actions on vascular cells where they exhibit anti-inflammatory and anti-proliferative properties. Hence PPAR agonists potentially can affect atherogenesis both via metabolic effects and direct effects on the vessel wall. We tested whether the dual PPAR-α/γ agonist, tesaglitazar (TZ), would reduce atherosclerosis in a non-diabetic, atherosclerosis-prone mouse model, independent of effects on plasma lipids.